LONDON & BOULDER, Colo. - Friday, 27. February 2026


New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy.



(BUSINESS WIRE)--1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets.

The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces institutional-grade protection designed to prevent performance losses resulting from credit degradation between wrapping and minting.

Luke Hanley, Founder and CEO of 1089 Inc. ... Read more »

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods
Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods
Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year
Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion
(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.

“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical de ... Read more »

Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1 Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5 (BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nod ... Read more »